The $0.6 million increase was primarily driven by increases of $0.2 million in salaries, payroll related expenses and stock based compensation as a result of increased headcount and a $0.7 million increase in clinical related activities.

filing / Aug 13, 2026 / receipt

The increase of $0.9 million was primarily due to increases of $1.3 million in clinical related activities and $0.6 million in salaries, payroll related expenses and stock based compensation as a result of increased headcount.

filing / Aug 13, 2026 / receipt

If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Critical Accounting Policies and Estimates This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited condensed consolidated interim financial statements, which we have prepared in accordance with accounting principles gener

filing / Aug 13, 2026 / receipt

If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements.

filing / Aug 13, 2026 / receipt

The increase of $0.2 million was primarily due to increases of $0.4 million in salaries, payroll related expenses and stock based compensation as a result of increased headcount and $0.1 million increased spend in clinical related activities.

filing / May 14, 2026 / receipt

These increases will likely include increases related to the hiring of additional personnel and legal, regulatory, and other fees and services associated with maintaining compliance with the New York Stock Exchange American Company Guide and SEC requirements, director and officer insurance costs, and investor relations costs associated with being a public company.

filing / May 14, 2026 / receipt

If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Critical Accounting Policies and Estimates This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses and analyzes data in our unaudited condensed consolidated interim financial statements, which we have prepared in accordance with accounting principles gener

filing / May 14, 2026 / receipt

If we are unable to raise capital, we will need to delay, reduce, or terminate planned activities to reduce costs. Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements.

filing / May 14, 2026 / receipt

Aircraft N283CE, registered to CUMMINS INC, landed at KHSV (Huntsville International Airport) on 2026-09-02. KHSV is 7.0 miles from the headquarters of Serina Therapeutics Inc. in HUNTSVILLE, AL.

company_statement / Sep 2, 2026 / receipt